Cannanetic resolves CYP, CES, and UGT-mediated interactions between cannabinoids and medications, and shows where published in vitro inhibition may become relevant. Every Ki is traced to its source. The range is not a dose.
Informational clinical decision support. Not a substitute for independent clinical judgment.
Cannanetic© 2026 Ivan Shamrai. All rights reserved. Owned by Ivan Shamrai.
Information first · tools for clinicians
Cannanetic is built for registered healthcare professionals. The pages below are a briefing on the plant, the evidence, and Australian access law — written for clinicians and pharmacists who have not prescribed or dispensed these products before. Clinical tools stay behind sign-in and do not collect patient data.
Short answers for practitioners who have not worked with medicinal cannabis before. Each statement is cited. Rules below are as at September 2026 — follow the linked official page if it has moved.
Products that are almost entirely CBD can sit in Schedule 4. Products that contain THC are typically Schedule 8. The exact cut is in the Poisons Standard — confirm it for the product in hand.
Prescriber and pharmacist rulesOils, capsules, sprays, pastilles, and inhaled flower are not interchangeable. Route changes how quickly cannabinoids appear in blood and how long they last.
Read the briefingA lawful prescription, the matching TGA approval for unregistered products, schedule-appropriate storage and records, and no substitution of an unregistered product.
Jurisdiction notesLegally manufactured cannabis products prescribed by a registered health practitioner. In Australia they are regulated medicines, not a general-sale herbal.
Read the briefingPlant and related compounds that act on the endocannabinoid system. The two you will see on almost every label are THC and CBD.
Read the briefingThe National Academies (the successor to the Institute of Medicine on this topic) judged oral cannabinoids conclusive for chemotherapy nausea, and cannabis substantial for adult chronic pain and patient-reported MS spasticity.
Read the briefingTGA guidance lists previous or current psychosis, a concurrent active mood or anxiety disorder, unstable cardiovascular disease, and pregnancy, planning pregnancy, or breastfeeding.
Read the briefingUnapproved products go through TGA Special Access Scheme Category B or Authorised Prescriber, plus state and territory poisons law. ARTG-registered products do not need SAS or AP.
State and territory rulesCannabinoids are substrates, inhibitors, or inducers of enzymes such as CYP3A4, CYP2C9, CYP2C19, CES, and UGTs. That can change levels of other medicines — or of the cannabinoids themselves.
Read the briefingWhat it is, what cannabinoids are, what the National Academies review supports, and why interactions matter.
TGA pathways plus prescriber and pharmacist rules for each Australian state and territory.
Opioid replacement therapy: PBS listing plus prescriber and pharmacist program rules in each jurisdiction.
Aromatic constituents, the limits of the entourage claim, and what recent experimental data do and do not show.
A clinical decision-support tool for registered health professionals: interactions, kinetics, and sources.
Informational pages for the public and for clinicians. Clinical tools are for registered healthcare professionals. Legal notes are a reading aid, not advice.
Cannanetic© 2026 Ivan Shamrai. All rights reserved. Owned by Ivan Shamrai.